As­traZeneca caps PD-L1/CT­LA-4/chemo com­bo come­back with OS win. Is treme­li­mum­ab fi­nal­ly ready for ap­proval?

As­traZeneca’s close­ly-watched PO­SEI­DON study con­tin­ues to be the rare bright spot in its push for an in-house PD-L1/CT­LA-4 com­bo.

Com­bin­ing Imfinzi and treme­li­mum­ab with physi­cians’ choice of chemother­a­py helped pa­tients with stage IV non-small cell lung can­cer live longer, the com­pa­ny re­port­ed — mark­ing the first time the still-ex­per­i­men­tal treme­li­mum­ab has demon­strat­ed an OS ben­e­fit.

For As­traZeneca and CEO Pas­cal So­ri­ot, the pos­i­tive read­out — which is de­void of num­bers — of­fers much-need­ed val­i­da­tion for the big bet they made on Imfinzi plus treme­li­mum­ab, af­ter the PD-L1/CT­LA-4 reg­i­men failed mul­ti­ple tri­als in head and neck can­cer as well as lung can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER